Torrent Pharmaceuticals Moat Analysis: Score & Risks
Torrent Pharmaceuticals Ltd.
A first-pass moat teardown of Torrent Pharmaceuticals Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.
First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence.
Torrent Pharmaceuticals Ltd. scores 5.27 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.
Seven dimensions of moat
Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.
“Our field force strength at the end of the quarter stands at 6,900 versus 6,800 last quarter, and we remain on track to close the financial year with a strength of just over 7,000.”
“the inflation is pretty low, and the price increase we are seeing is not like old times. Nowadays, we are seeing 4 and 5, which also companies are not able to take because of competition.”
“The current development pipeline reflects a broad and well balanced portfolio encompassing orphan drugs, NCE-1, first to file (FTF), injectables, and high value as well as high volume products.”
“The company's US market revenue fell to USD102 million during 9MFY22 (FY21: USD166 million, FY20: USD207 million), led by lack of new approvals and the ongoing erosion in the base business”
D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.
The barrier gate — first-pass
Effective barrier 6.0 — clears the gate. First-pass estimate.
Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.
The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.
Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.
Where this note fits. This company is one of 113 Indian companies we have scored for moat durability — 88 narrow, 25 narrow-trending-wide, none wide. The full ranked read: Wide-Moat Stocks in India: We Scored 113 Companies and Found None. Every score, dimension by dimension, is free in the Moat Screener.
Member discussion